|Bid||75.40 x 1200|
|Ask||75.47 x 800|
|Day's Range||71.65 - 75.60|
|52 Week Range||47.57 - 125.00|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||149.41|
Over the past couple of months, investors have been taken on the wildest roller-coaster ride in the stock market's history. In September 2017, it was disclosed by Intercept, and days later by the Food and Drug Administration (FDA), that some PBC patients (19, according to the FDA) taking Ocaliva had died.
Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (ICPT). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether Intercept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intercept Pharmaceuticals, Inc. ("Intercept" or "the ...
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
An unexpected delay for Intercept Pharmaceuticals' liver-disease treatment led ICPT stock to crumble on Friday. Intercept is working on obeticholic acid in nonalcoholic steatohepatitis.
Investors are feeling more uncertainty about whether obeticholic acid will be approved as a treatment for liver fibrosis due to nonalcoholic steatohepatitis.
What happened? Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are plunging on Friday after the company announced some bad news regarding its new drug application (NDA) for Ocaliva as a treatment for fibrosis (buildup of scar tissue) in the liver due to nonalcoholic steatohepatitis (NASH).
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that based on discussions earlier this week, the U.S. Food and Drug Administration (FDA) has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s new drug application (NDA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH) has been postponed. The postponement will accommodate the review of additional data requested by the FDA that the company intends to submit within the next week. The FDA has indicated that it will reach out to Intercept in the near future with a new proposed AdCom date.
Following the March 2009 stock market bottom, all three major U.S. indexes ended up at least quadrupling in value, if not delivering even more robust returns. Then the coronavirus disease 2019 (COVID-19) pandemic came along and disrupted the economy, labor force, and stock market like nothing we'd ever seen before. Uncertainties tied to the coronavirus pushed the broad-based S&P 500 into bear market territory in just 17 trading sessions, marking the fastest decline into a bear market in history.
Intercept Pharmaceuticals (NASDAQ: ICPT) and Gilead Sciences (NASDAQ: GILD) don't compete against each other at this point, but that just might change in the not-too-distant future. Which of these two biotech stocks is the better pick for long-term investors? Ocaliva is currently approved in the U.S. and in other countries for treating primary biliary cholangitis (PBC), a liver disease that damages bile ducts.
Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) rose 2.5% after the company reported Q1 results.Quarterly Results Earnings per share rose 5.61% over the past year to ($2.86), which beat the estimate of ($2.95).Revenue of $72,652,000 up by 39.04% year over year, which beat the estimate of $69,660,000.Guidance Earnings guidance hasn't been issued by the company for now.Intercept Pharmaceuticals hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 11, 2020View more earnings on ICPTTime: 08:05 PM ETWebcast URL: https://edge.media-server.com/mmc/p/9gvete46Recent Stock Performance Company's 52-week high was at $125.0052-week low: $47.57Price action over last quarter: Up 0.30%Company Overview Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.See more from Benzinga * Coty: Q3 Earnings Insights * Recap: Golub Capital BDC Q2 Earnings * Univar: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Intercept (ICPT) delivered earnings and revenue surprises of 2.72% and 6.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What happened Intercept Pharmaceuticals (NASDAQ: ICPT), a mid-cap liver disease specialist, saw its shares rise by a healthy 40.3% over the course of April, according to data from S&P Global Market Intelligence.
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2020. Ocaliva net sales in the first quarter of 2020 were comprised of U.S. net sales of $50.8 million and ex-U.S. net sales of $21.9 million, as compared to U.S. net sales of $38.0 million and ex-U.S. net sales of $13.8 million in the prior year quarter.
NEW YORK, May 06, 2020 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
Namely, all stock market corrections and bear markets in history have proved to be a surefire buying opportunity for long-term investors. It's a telltale model that banking customers tend to have short-term memories when it comes to wrongdoing.
If you're interested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), then you might want to consider its beta (a...
NEW YORK, April 27, 2020 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments Continue reading...